AC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic Scan
By Don Nico Forbes
AC Immune said its partner Life Molecular Imaging received fast-track designation from the U.S. Food and Drug Administration for PI-2620, a diagnostic scan targeting neurodegenerative diseases.
The biopharmaceutical company said Wednesday that the designation was granted for clinical development across three neurodegenerative conditions: Alzheimer's disease, progressive supranuclear palsy and corticobasal degeneration.
PI-2620 is a next-generation positron emission tomography imaging agent developed as part of a research collaboration between AC Immune and LMI. It is currently in phase 3 trials for detecting Tau pathology in Alzheimer's disease, the company noted.
Tau proteins--which are involved in the stabilization of neurons--are a hallmark of several neurodegenerative disorders.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
August 28, 2024 09:44 ET (13:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States